$TDOC
Teladoc Health, Inc.

2020 Q4 Form 10-Q Financial Statement

#000155837020013035 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $383.3M $288.8M $138.0M
YoY Change 144.94% 109.33% 24.34%
Cost Of Revenue $122.9M $104.7M $42.80M
YoY Change 122.02% 144.69% 25.26%
Gross Profit $260.4M $184.1M $95.17M
YoY Change 157.48% 93.43% 23.93%
Gross Profit Margin 67.94% 63.74% 68.98%
Selling, General & Admin $531.7M $83.23M $54.80M
YoY Change 768.32% 51.87% 17.56%
% of Gross Profit 204.19% 45.21% 57.58%
Research & Development $92.70M $29.96M $15.75M
YoY Change 470.6% 90.26% 15.98%
% of Gross Profit 35.6% 16.27% 16.55%
Depreciation & Amortization $33.16M $15.37M $11.42M
YoY Change 199.01% 34.59% 17.13%
% of Gross Profit 12.73% 8.35% 12.0%
Operating Expenses $661.4M $113.2M $70.55M
YoY Change 753.65% 60.44% 17.2%
Operating Profit -$401.0M -$19.73M -$19.94M
YoY Change 2472.49% -1.1% 26.4%
Interest Expense -$20.80M -$17.20M -$7.700M
YoY Change 173.68% 123.38% 0.0%
% of Operating Profit
Other Income/Expense, Net -$252.0K
YoY Change
Pretax Income -$479.4M -$38.17M -$27.64M
YoY Change 1969.14% 38.09% 17.92%
Income Tax -$85.50M -$2.300M -$7.300M
% Of Pretax Income
Net Earnings -$394.0M -$35.88M -$20.35M
YoY Change 1968.89% 76.37% -12.54%
Net Earnings / Revenue -102.79% -12.42% -14.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.064M -$429.4K -$281.2K
COMMON SHARES
Basic Shares Outstanding 145.0M 81.23M 72.04M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $786.6M $1.190B $490.9M
YoY Change 52.12% 142.5% 3.78%
Cash & Equivalents $733.3M $1.187B $475.2M
Short-Term Investments $53.25M $3.070M $15.63M
Other Short-Term Assets $47.00M $22.00M $13.00M
YoY Change 235.71% 69.23% 18.18%
Inventory $56.50M $11.58M
Prepaid Expenses
Receivables $169.3M $85.80M $53.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.060B $1.310B $558.0M
YoY Change 80.2% 134.79% 6.68%
LONG-TERM ASSETS
Property, Plant & Equipment $28.55M $20.36M $10.02M
YoY Change 177.3% 103.21% 0.21%
Goodwill $14.58B $1.691B $737.6M
YoY Change 1854.38% 129.29%
Intangibles $2.021B $386.6M $228.8M
YoY Change 796.36% 68.93%
Long-Term Investments
YoY Change
Other Assets $18.36M $7.117M $6.367M
YoY Change 180.47% 11.78% 536.7%
Total Long-Term Assets $16.70B $2.139B $1.010B
YoY Change 1545.18% 111.72% -0.15%
TOTAL ASSETS
Total Short-Term Assets $1.060B $1.310B $558.0M
Total Long-Term Assets $16.70B $2.139B $1.010B
Total Assets $17.76B $3.449B $1.568B
YoY Change 1007.75% 119.93% 2.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $46.03M $21.41M $6.068M
YoY Change 407.22% 252.8% 21.36%
Accrued Expenses $156.0M $110.0M $54.00M
YoY Change 168.97% 103.7% 42.11%
Deferred Revenue $14.36M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $42.56M $14.00M
YoY Change
Total Short-Term Liabilities $332.6M $200.8M $85.20M
YoY Change 268.87% 135.7% 46.9%
LONG-TERM LIABILITIES
Long-Term Debt $1.390B $963.0M $434.0M
YoY Change 215.91% 121.89% 6.11%
Other Long-Term Liabilities $1.616M $1.033M $7.156M
YoY Change -82.51% -85.56% 19.27%
Total Long-Term Liabilities $1.616M $1.033M $7.156M
YoY Change -82.51% -85.56% -98.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $332.6M $200.8M $85.20M
Total Long-Term Liabilities $1.616M $1.033M $7.156M
Total Liabilities $334.3M $201.9M $92.36M
YoY Change 236.22% 118.56% -81.78%
SHAREHOLDERS EQUITY
Retained Earnings -$992.7M -$598.7M -$488.5M
YoY Change 95.59% 22.56%
Common Stock $16.86B $2.835B $1.510B
YoY Change 995.53% 87.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.88B $2.231B $993.7M
YoY Change
Total Liabilities & Shareholders Equity $17.76B $3.449B $1.568B
YoY Change 1007.75% 119.93% 2.18%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$394.0M -$35.88M -$20.35M
YoY Change 1968.89% 76.37% -12.54%
Depreciation, Depletion And Amortization $33.16M $15.37M $11.42M
YoY Change 199.01% 34.59% 17.13%
Cash From Operating Activities -$114.9M $32.20M $13.49M
YoY Change -734.33% 138.7% 32.51%
INVESTING ACTIVITIES
Capital Expenditures -$8.650M -$9.300M -$3.290M
YoY Change 155.16% 182.67% 57.42%
Acquisitions
YoY Change
Other Investing Activities -$405.3M -$146.2M $16.47M
YoY Change -3231.92% -987.43% 545.88%
Cash From Investing Activities -$413.9M -$155.5M $13.20M
YoY Change -4438.89% -1277.73% 2769.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.44M 420.0K 9.150M
YoY Change 601.59% -95.41% -97.32%
NET CHANGE
Cash From Operating Activities -114.9M 32.20M 13.49M
Cash From Investing Activities -413.9M -155.5M 13.20M
Cash From Financing Activities 70.44M 420.0K 9.150M
Net Change In Cash -458.4M -122.8M 35.84M
YoY Change -1315.99% -442.75% -89.82%
FREE CASH FLOW
Cash From Operating Activities -$114.9M $32.20M $13.49M
Capital Expenditures -$8.650M -$9.300M -$3.290M
Free Cash Flow -$106.3M $41.50M $16.78M
YoY Change -594.14% 147.32% 36.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
396818000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72761941
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84358345
tdoc Number Of Service Corporations Consolidated As Variable Interest Entities
NumberOfServiceCorporationsConsolidatedAsVariableInterestEntities
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
dei Entity Central Index Key
EntityCentralIndexKey
0001477449
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37477
dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
635-2002
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TDOC
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
144960748
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1187299000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
514353000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
3070000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2711000
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4661000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3787000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
85803000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56948000
CY2020Q3 us-gaap Inventory Net
InventoryNet
11578000
CY2019Q4 us-gaap Inventory Net
InventoryNet
0
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22293000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13990000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
1310043000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
588002000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20364000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10296000
CY2020Q3 us-gaap Goodwill
Goodwill
1691355000
CY2019Q4 us-gaap Goodwill
Goodwill
746079000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
386573000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
225453000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33933000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26452000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7117000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6545000
CY2020Q3 us-gaap Assets
Assets
3449385000
CY2019Q4 us-gaap Assets
Assets
1602827000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
21408000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9075000
CY2020Q3 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
65130000
CY2019Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
34439000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
53957000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
34201000
CY2020Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
46721000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12466000
CY2020Q3 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13609000
CY2019Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
0
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
200825000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
90181000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1033000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9239000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30326000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24994000
CY2020Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4884000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2300000
CY2020Q3 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9901000
CY2019Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
0
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
17896000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
21678000
CY2020Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
953484000
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
440410000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84358345
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72761941
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
84000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
73000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2835274000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1538716000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-598694000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-507525000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5628000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17239000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2231036000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1014025000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3449385000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1602827000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
288812000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
137969000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
710641000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
396818000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
104725000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42799000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
267887000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
129110000
CY2020Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
52302000
CY2019Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
31321000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
132395000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
84341000
CY2020Q3 us-gaap Selling Expense
SellingExpense
23483000
CY2019Q3 us-gaap Selling Expense
SellingExpense
16120000
us-gaap Selling Expense
SellingExpense
60110000
us-gaap Selling Expense
SellingExpense
48164000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29958000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15746000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72244000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48398000
CY2020Q3 tdoc Legal And Regulatory Expense
LegalAndRegulatoryExpense
2812000
CY2019Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1995000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
30686000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4143000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56930000
us-gaap Costs And Expenses
CostsAndExpenses
758556000
us-gaap Costs And Expenses
CostsAndExpenses
461672000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38681000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
156433000
CY2019Q3 tdoc Legal And Regulatory Expense
LegalAndRegulatoryExpense
1634000
tdoc Legal And Regulatory Expense
LegalAndRegulatoryExpense
6266000
tdoc Legal And Regulatory Expense
LegalAndRegulatoryExpense
5239000
CY2020Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
25395000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
113212000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
12932000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9617000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
32535000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
29065000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
308537000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
157913000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19725000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19944000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47915000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64854000
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1227000
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8978000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-17222000
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-7700000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-39676000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-21432000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38174000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27644000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96569000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-86286000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2290000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7298000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6466000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-35884000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-20346000
us-gaap Net Income Loss
NetIncomeLoss
-91169000
us-gaap Net Income Loss
NetIncomeLoss
-79820000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.11
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83607902
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72151094
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77821073
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71601790
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-35884000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-20346000
us-gaap Net Income Loss
NetIncomeLoss
-91169000
us-gaap Net Income Loss
NetIncomeLoss
-79820000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16285000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15516000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11610000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14988000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19599000
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
58000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18421000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17554000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1875000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17368000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-23000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
37000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
16285000
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15493000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
11610000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15025000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35862000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79559000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94808000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1014025000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14830000
CY2020Q1 tdoc Stock Issued During Period Value Restricted Stock Units
StockIssuedDuringPeriodValueRestrictedStockUnits
0
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29603000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1000177000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18683000
CY2020Q2 tdoc Stock Issued During Period Value Restricted Stock Units
StockIssuedDuringPeriodValueRestrictedStockUnits
0
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2473000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22142000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12880000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-25682000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1294929000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7113000
CY2020Q3 tdoc Stock Issued During Period Value Restricted Stock Units
StockIssuedDuringPeriodValueRestrictedStockUnits
0
CY2020Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
918818000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21178000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16285000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-35884000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2231036000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1013119000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8854000
CY2019Q1 tdoc Stock Issued During Period Value Restricted Stock Units
StockIssuedDuringPeriodValueRestrictedStockUnits
0
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13523000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3788000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-30150000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1001558000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6847000
CY2019Q2 tdoc Stock Issued During Period Value Restricted Stock Units
StockIssuedDuringPeriodValueRestrictedStockUnits
0
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4316000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-29324000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1002640000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9119000
CY2019Q3 tdoc Stock Issued During Period Value Restricted Stock Units
StockIssuedDuringPeriodValueRestrictedStockUnits
0
CY2019Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17833000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15516000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-20346000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
993738000
us-gaap Net Income Loss
NetIncomeLoss
-91169000
us-gaap Net Income Loss
NetIncomeLoss
-79820000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38029000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33860000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2320000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1717000
us-gaap Share Based Compensation
ShareBasedCompensation
61151000
us-gaap Share Based Compensation
ShareBasedCompensation
48245000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-4096000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-10288000
tdoc Accretion Of Interest
AccretionOfInterest
29459000
tdoc Accretion Of Interest
AccretionOfInterest
19422000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8978000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16450000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12386000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5906000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2219000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2392000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-140000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-73000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6584000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1976000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
17269000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
14304000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
9329000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1813000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15348000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6708000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4360000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1481000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2809000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2599000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61425000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11747000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2872000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2847000
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
14515000
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
5000000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
159663000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
11204000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-177050000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15466000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40627000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24820000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
24070000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
228153000
tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
0
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
1924000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
0
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
4427000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2473000
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
4658000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
39165000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1875000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
326000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
-1642000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
788700000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25053000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
673075000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
52266000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-129000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1013000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
514353000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
423989000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1187299000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
475242000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
786000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
846000
us-gaap Interest Paid
InterestPaid
5612000
us-gaap Interest Paid
InterestPaid
6112000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
85800000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
36800000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6700000
CY2020Q3 tdoc Contract With Customer Refunds Issued
ContractWithCustomerRefundsIssued
3300000
CY2019Q3 tdoc Contract With Customer Refunds Issued
ContractWithCustomerRefundsIssued
900000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health” or the “Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in providing virtual healthcare services with a focus on high quality, lower costs, and improved outcomes around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), the leading provider of enterprise telehealth solutions for hospitals and health systems. See Note 4 “Business Acquisition”. On August 5, 2020, Teladoc Health announced that it had entered into a definitive merger agreement with Livongo Health, Inc. (“Livongo”), which represents a transformational opportunity to improve the delivery, access and experience of healthcare for consumers around the world. The merger closed on October 30, 2020. See Note 16 “Subsequent Event”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
2
tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
11
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. On an ongoing basis, management evaluates its estimates compared to historical experience and trends, which form the basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. Key estimates are used for revenue recognition criteria, purchase accounting, net realizable value for inventories, useful lives of property and equipment as well as rental equipment, carrying value of all long-lived assets, recognition, accounting for convertible notes transactions, disclosure of contingent liabilities, and assumptions used in determining appropriate accounting treatment of leasing transactions, among other material accounting policies as described in the Summary of Significant Accounting policies in this Quarterly Report on Form 10-Q and in the 2019 Form 10-K.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Certain prior year amounts have been reclassified to conform to the current year presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Cost of revenue includes product depreciation but excludes all other forms of depreciation and amortization.</p>
tdoc Contract With Customer Term
ContractWithCustomerTerm
P1Y
tdoc Payment Terms
PaymentTerms
P30D
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
288812000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
137969000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
710641000
tdoc Contract With Customer Refunds Issued
ContractWithCustomerRefundsIssued
7000000.0
tdoc Contract With Customer Refunds Issued
ContractWithCustomerRefundsIssued
2100000
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
511864000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
125291000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
386573000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
319796000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
94343000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
225453000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11700000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
26400000
CY2019Q4 us-gaap Goodwill
Goodwill
746079000
CY2018Q4 us-gaap Goodwill
Goodwill
737197000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
937463000
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
10604000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
7813000
CY2019 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1722000
CY2020Q3 us-gaap Goodwill
Goodwill
1691355000
CY2019Q4 us-gaap Goodwill
Goodwill
746079000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3011000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1535000
CY2020Q3 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
19255000
CY2019Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
10618000
CY2020Q3 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
3575000
CY2019Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
3298000
CY2020Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
2364000
CY2019Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
1077000
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
6492000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
838000
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2704000
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2859000
CY2020Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3205000
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1263000
CY2020Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
5983000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2810000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7276000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5088000
CY2020Q3 tdoc Accrued Earn Out Current
AccruedEarnOutCurrent
4552000
CY2019Q4 tdoc Accrued Earn Out Current
AccruedEarnOutCurrent
0
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6713000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5053000
CY2020Q3 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
65130000
CY2019Q4 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
34439000
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
4712000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
13161000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
6533000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
962000
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
25368000
CY2020Q3 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
4037000
CY2020Q3 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
12058000
CY2020Q3 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
6437000
CY2020Q3 tdoc Advances From Financing Companies Customer Payments Due Year Four
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearFour
978000
CY2020Q3 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
23510000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20908000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17354000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61151000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48245000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5400000
CY2020Q3 tdoc Income Tax Benefit Related To Expiration Of Statute Of Limitations For Uncertain Tax Position
IncomeTaxBenefitRelatedToExpirationOfStatuteOfLimitationsForUncertainTaxPosition
2000000.0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6500000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001558370-20-013035-index-headers.html Edgar Link pending
0001558370-20-013035-index.html Edgar Link pending
0001558370-20-013035.txt Edgar Link pending
0001558370-20-013035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20200930.xsd Edgar Link pending
tdoc-20200930ex311a840be.htm Edgar Link pending
tdoc-20200930ex3120da0d5.htm Edgar Link pending
tdoc-20200930ex321c3d40a.htm Edgar Link pending
tdoc-20200930ex32291a51d.htm Edgar Link pending
tdoc-20200930x10q.htm Edgar Link pending
tdoc-20200930x10q_htm.xml Edgar Link completed
tdoc-20200930_cal.xml Edgar Link unprocessable
tdoc-20200930_def.xml Edgar Link unprocessable
tdoc-20200930_lab.xml Edgar Link unprocessable
tdoc-20200930_pre.xml Edgar Link unprocessable